Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
October 24 2019 - 4:30PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, will report third quarter 2019
financial results after the Nasdaq Global Market closes on
Thursday, November 7, 2019. Subsequently, at 4:30 p.m. E.T., the
Company will host a conference call to discuss its third quarter
2019 financial results and to provide a corporate update.
The conference call may be accessed by dialing
(844) 534-7313 for domestic callers and (574) 990-1451 for
international callers. The passcode for the call is 8998299. Please
specify to the operator that you would like to join the "Sarepta
Third Quarter 2019 Earnings Call." The conference call will be
webcast live under the investor relations section of Sarepta's
website at www.sarepta.com and will be archived there following the
call for 90 days. Please connect to Sarepta's website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.
About Sarepta
TherapeuticsSarepta is at the forefront of precision
genetic medicine, having built an impressive and competitive
position in Duchenne muscular dystrophy (DMD) and more recently in
gene therapies for Limb-girdle muscular dystrophy diseases (LGMD),
MPS IIIA, Pompe and other CNS-related disorders, totaling over 20
therapies in various stages of development. The Company’s programs
and research focus span several therapeutic modalities, including
RNA, gene therapy and gene editing. Sarepta is fueled by an
audacious but important mission: to profoundly improve and extend
the lives of patients with rare genetic-based diseases. For more
information, please visit www.sarepta.com.
Internet Posting of
InformationWe routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052iestepan@sarepta.com
Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024